Document Detail

MedLine Citation:
PMID:  22037033     Owner:  NLM     Status:  MEDLINE    
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.
Keith T Flaherty; Uma Yasothan; Peter Kirkpatrick
Related Documents :
22037033 - Vemurafenib.
22119603 - Exaggerated inflammatory response and bony resorption from bmp-2 use in a pediatric for...
17518553 - Development of the weight- and body-related shame and guilt scale (web-sg) in a nonclin...
Publication Detail:
Type:  News     Date:  2011-10-31
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  10     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-10-31     Completed Date:  2011-12-20     Revised Date:  2012-06-21    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  811-2     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Drug Resistance, Neoplasm / drug effects,  genetics
Indoles / pharmacology,  therapeutic use*
Melanoma / drug therapy*,  enzymology,  genetics
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*,  genetics,  metabolism
Sulfonamides / pharmacology,  therapeutic use*
Reg. No./Substance:
0/Indoles; 0/PLX4032; 0/Sulfonamides; EC protein, human; EC Proteins B-raf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical pharmacology as a cornerstone of orphan drug development.
Next Document:  Quantifying factors for the success of stratified medicine.